Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 8/20 | 0.46 |
| ▸ | PDE2A | O00408 | 7/20 | 0.43 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579798 | 0.76 | PDE2A (0.41) | PDE2AALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3859248 | 0.73 | CDK2 (0.58) | — | |
| SCHEMBL23579585 | 0.69 | PDE2A (0.39) | PDE2AKMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2194466 | 0.68 | PDE2A (0.71) | BCDIN3DPDE2AALDH1A1KMT2ACYP1A2 | |
| SCHEMBL3852231 | 0.67 | CYP19A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL2494591 | 0.66 | CFTR (0.58) | ALDH1A1CYP1A2CYP3A4GAA | |
| SCHEMBL29685062 | 0.66 | PDE2A (0.60) | PDE2AALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL130521 | 0.66 | PDE2A (0.60) | PDE2AALDH1A1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL2193810 | 0.66 | CYP1A2 (0.79) | BCDIN3DPDE2AKMT2ACYP1A2CYP3A4 | |
| SCHEMBL28855678 | 0.66 | BCDIN3D (0.42) | BCDIN3DALDH1A2ALDH1A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2252616-B1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2252616-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009097446-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | BCDIN3D 1803/4885PDE2A 2052/4885ALDH1A2 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.